Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Nov 2018
Randomized Controlled Trial Multicenter StudyMaintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
Psoriasis is a chronic disease that may require long-term treatment. Ixekizumab (IXE), which is a high-affinity monoclonal antibody that selectively targets interleukin 17A, is an approved therapy for patients with moderate-to-severe plaque psoriasis. ⋯ IXE sustained high responses with clearance of skin and nail lesions, with no new safety concerns through 3 years.
-
J. Am. Acad. Dermatol. · May 2018
Randomized Controlled Trial Multicenter Study Comparative StudyEfficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD). ⋯ When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant improvement and was well tolerated in patients with moderate-to-severe AD.
-
J. Am. Acad. Dermatol. · Jan 2018
Randomized Controlled Trial Multicenter Study Comparative StudyAdalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Previous clinical trials have not evaluated improvement in nail psoriasis as a primary end point. ⋯ After 26 weeks of adalimumab treatment, significant improvements were seen in the primary and all ranked secondary end points and in signs and symptoms of moderate-to-severe nail psoriasis versus with placebo and no new safety risks were identified.
-
J. Am. Acad. Dermatol. · Nov 2017
Randomized Controlled Trial Multicenter StudyEfficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A, is efficacious in treating moderate-to-severe plaque psoriasis through 60 weeks. ⋯ Ixekizumab is well tolerated and demonstrates persistent efficacy through 108 weeks.
-
J. Am. Acad. Dermatol. · Oct 2017
Multicenter StudyLong-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
Long-term topical treatment is often required for atopic dermatitis (AD), a chronic inflammatory skin disease. ⋯ Crisaborole ointment had a low frequency of treatment-related AEs over 48 weeks of treatment of patients with AD.